Non-Hodgkin Lymphoma

John P. Leonard, MD, discusses the potential for lenalidomide, idelalisib, and ibrutinib in follicular lymphoma, possible combination therapies, and challenges that remain in the treatment of the disease.

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center, and an assistant professor of Oncology at the University of South Florida, discusses KTE-C19 for the treatment of refractory aggressive non-Hodgkin lymphoma (NHL).

Frederick Locke, MD, discusses the potential for KTE-C19 in non-Hodgkin lymphoma.

Adding brentuximab vedotin (Adcetris) to frontline R-CHOP produced a greater than 80% response rate—including complete remissions in three-fourths of patients—as a treatment for CD30+ diffuse large B-cell lymphoma.

Jeff Sharman, MD, director of Research with Willamette Valley Cancer Institute and Research Center, medical director of Hematology Research for The US Oncology Network, discusses clinical activity of entospletinib in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who were previously treated with a B-cell receptor pathway signaling inhibitor.

Daniel R. Vlock, MD, founder and CEO, Alopexx Pharmaceuticals, discusses a phase I/II study of an anti–CD20 interleukin-2 immunocytokine in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

The FDA has approved a rapid infusion formulation of bendamustine under the trade name Bendeka for the treatment of patients with chronic lymphocytic leukemia or indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Thomas J. Kipps, MD, PhD, deputy director of Research, Moores University of California, San Diego Cancer Center, professor of Medicine, University of California San Diego, School of Medicine, discusses results of the RESONATE-2 study, which compared ibrutinib versus chlorambucil in elderly patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

More than 80% of patients with treatment-refractory Waldenstrom's macroglobulinemia responded to single-agent therapy with ibrutinib, according to results of a preliminary clinical trial.

Updated findings from early stage clinical trials exploring chimeric antigen receptor-modified T-cell therapies continue to highlight the effectiveness of these approaches for patients with non-Hodgkin lymphoma.

Dr. Andre Goy discusses combining novel agents with R-CHOP for the treatment of large-cell lymphoma.

John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses therapies available for patients with indolent B-cell Non-Hodgkin lymphoma.

Mutations in MYD88 and CXCR4 can effectively be used to tailor treatment for patients with Waldenström's macroglobulinemia.

The use of radiation therapy has declined despite evidence demonstrating it is often more beneficial than single-agent chemotherapy or observation-alone in patients with low-grade follicular lymphoma.

Elizabeth J. Shpall, MD, professor, deputy department chair, Department of Stem Cell Transplantation, Division of Cancer Medicine, medical director, Cell Therapy Laboratory, director, Cord Blood Bank, the University of Texas MD Anderson Cancer Center, discusses idelalisib and ibrutinib for the treatment of patients with chronic lymphocytic leukemia.

The heterogeneity of mantle cell lymphoma will require new combination strategies to improve outcomes.

Lack of improvement in failure-free survival for patients with follicular lymphoma has fueled interest in new treatment strategies that might offer promise of better outcomes.

Patients with follicular lymphoma progressing within 2 years on first-line R-CHOP have a 5-year overall survival rate of only 50%, compared with 90% in longer responders.

The anti-CD20 agent obinutuzumab improved overall response and had acceptable toxicity compared with rituximab in patients with relapsed indolent non-Hodgkin Lymphoma, according to the final results from the GAUSS study.

John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses the phase III SELENE study, which is examining the addition of ibrutinib to either R-CHOP or bendamustine plus rituximab for the treatment of patients with follicular lymphoma.

Ibrutinib had an overall response rate of 37% in patients with activated B-cell-like diffuse large B-cell lymphoma.

Tahir Latif, MD, discusses results of a recent study which found that men may have a lower rate of survival among patients with diffuse large B-cell lymphoma.

Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Deputy Chief, Division of Hematology/Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, discusses the phase III GADOLIN study, which looks at the anti-CD20 agent obinutuzumab (Gazyva) and bendamustine compared with bendamustine alone in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).